Sinovac Biotech (SVA) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Sinovac Biotech SVA is currently developing the following drugs: Participants Will Receive One Dose Of Vaccine (0.5 Ml) Of Sinovac Qiv, Vaxigrip Qiv, Ev71 Vaccine, Rabies Vaccine, Verorab, Rabies Vaccine (Serum-Free Vero Cell), Freeze-Dried, Verorab, Low-Dose Of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell), Medium-Dose Tetravalent Inactivated Enterovirus Vaccine (Vero Cell), High-Dose Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) ), Ev71 Inactivated Enterovirus Vaccine (Vero Cell) )(For Ages 6-71 Months）, Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, Enterovirus Type 71 Vaccine (Vero Cell), Inactivated, Sipv, Mmr, Hepa-I, Sipv, Quadrivalent Influenza Vaccine, Trivalent Influenza Vaccine, Low Dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, Medium Dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, High Dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, Enterovirus Type Ev71 Vaccine (Vero Cell), Inactivated. These drug candidates are in various stages of clinical development as the company works toward FDA approval.